Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailFractography survey on high cycle fatigue failure: Crack origin characterisation and correlations between mechanical tests and microstructure in Fe-C-Cr-Mo-X alloys
Tchuindjang, Jérôme Tchoufack ULg; Lecomte-Beckers, Jacqueline ULg

in International Journal of Fatigue (2007), 29(4), 713-728

Raw materials were cast from different specific processes in order to produce cleaner steels with a reduced amount of inclusions. Studied materials that are HSS hardened alloys belonging to the Fe-Cr-C-X ... [more ▼]

Raw materials were cast from different specific processes in order to produce cleaner steels with a reduced amount of inclusions. Studied materials that are HSS hardened alloys belonging to the Fe-Cr-C-X system were shared out in four groups depending on the tempering temperature and the presence of secondary and primary carbides. Both inclusions and carbides were roughly assessed by means of Image Analysis. Forging was done on all studied materials with different reduction ratios in order to highlight the texture influence oil mechanical properties. High cycle fatigue tests were made using the boundary method to allow a quick evaluation of results. Fractographic analyses carried out on broken samples led to the definition of four failure modes depending on the nature and the location of the point from which the crack was initiated in one hand, and the roughness of striations in the propagating area over and around the initiation point. Internal and surface crack initiation points were found, the latter being more harmful than the first ones. Though oxides appeared to be more detrimental than other inclusions, primary carbides were also found to be both crack initiation candidates and crack propagation enhancers. Various parameters likely to influence high cycle fatigue failures were finally defined, the most significant one dealing with the nature and location of embedded precipitates and the forging reduction ratio. (c) 2006 Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 177 (9 ULg)
See detailFracture (sociale, numérique etc.)
Vandeninden, Elise ULg

in Durand, Pascal (Ed.) Les nouveaux mots du pouvoir. Abécédaire critique. (2007)

Detailed reference viewed: 15 (1 ULg)
Full Text
See detailFracture (sociale, numérique, etc.)
Vandeninden, Elise ULg

in Quaderni : la Revue de la Communication (2007), 63

Detailed reference viewed: 28 (8 ULg)
Peer Reviewed
See detailFracture and Bone Mineral Density in Hemodialysis Patients
Fontaine, M. A.; Albert, Adelin ULg; Dubois, Bernard ULg et al

in Clinical Nephrology (2000), 54(3), 218-26

AIM: The aim of this cross-sectional study was to determine in hemodialysis patients the pattern of low trauma fracture, the ability of dual X-ray absorptiometry (DXA) to discriminate between patients ... [more ▼]

AIM: The aim of this cross-sectional study was to determine in hemodialysis patients the pattern of low trauma fracture, the ability of dual X-ray absorptiometry (DXA) to discriminate between patients with and without fracture, and the magnitude, distribution and mechanism of bone loss. PATIENTS AND METHODS: Eighty-eight patients were studied. Bone mineral density (BMD) was measured by DXA at lumbar spine (LS), femoral neck (FN) and 3 radius sites (UD, MID and 1/3R). In 11 patients (12.5%), 16 fractures occurred and were predominant at the distal forearm and ribs. RESULTS: Patients with fracture had a significatively lower BMD Z-score at LS (-1.34 +/- 1.66 vs -0.42 +/- 1.23), at FN (-1.58 +/- 1.25 vs -0.60 +/- 1.01), at MID radius (-2.59 +/- 1.34 vs -0.93 +/- 1.76) and 1/3 radius (-1.62 +/- 1.60 vs -0.39 +/- 1.32). They also had a longer history of dialysis (113 +/- 64 vs 53 +/- 65 months). Prevalence of osteoporosis varied from 23% at LS to 50% at MID radius. CONCLUSION: Multiple regression analysis showed that there was no influence of gender, age, parathormone status and primary renal disease on BMD. However, at FN, UD, MID and 1/3 radius, a significantly negative correlation was found between length of dialysis and BMD Z-score. By contrast at LS, there was a positive correlation between age at onset of dialysis and BMD Z-score. Despite occurrence of fracture at the fistula forearm, BMD levels were similar in both arms. [less ▲]

Detailed reference viewed: 21 (0 ULg)
Full Text
Peer Reviewed
See detailFracture de la hanche. Données épidémiologiques et approche thérapeutique
Reginster, Jean-Yves ULg

in Le Monde Médical de la Femme (1995), 8

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailFracture efficacy of monthly ibandronate and weekly bisphosphonate therapy: a retrospective cohort study
Reginster, Jean-Yves ULg; Blumentals, W.; Barr, C. et al

in Osteoporosis International (2008, April), 19(Suppl.1), 9

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailA fracture framework for Euler Bernoulli beams based on a full discontinuous Galerkin formulation/extrinsic cohesive law combination
Becker, Gauthier ULg; Noels, Ludovic ULg

in International Journal for Numerical Methods in Engineering (2011), 85(10), 12271251

A new full Discontinuous Galerkin discretization of Euler Bernoulli beam is presented. The main interest of this framework is its ability to simulate fracture problems by inserting a cohesive zone model ... [more ▼]

A new full Discontinuous Galerkin discretization of Euler Bernoulli beam is presented. The main interest of this framework is its ability to simulate fracture problems by inserting a cohesive zone model in the formulation. With a classical Continuous Galerkin method the use of the cohesive zone model is di cult because as insert a cohesive element between bulk elements is not straightforward. On one hand if the cohesive element is inserted at the beginning of the simulation there is a modification of the structure stiffness and on the other hand inserting the cohesive element during the simulation requires modification of the mesh during computation. These drawbacks are avoided with the presented formulation as the structure is discretized in a stable and consistent way with full discontinuous elements and inserting cohesive elements during the simulation becomes straightforward. A new cohesive law based on the resultant stresses (bending moment and membrane) of the thin structure discretization is also presented. This model allows propagating fracture while avoiding through-the-thickness integration of the cohesive law. Tests are performed to show that the proposed model releases, during the fracture process, an energy quantity equal to the fracture energy for any combination of tension-bending loadings. [less ▲]

Detailed reference viewed: 161 (74 ULg)
Full Text
Peer Reviewed
See detailFracture of piezoelectric materials with the X-FEM
Béchet, Eric ULg; Scherzer, Matthias; Kuna, Meinhard

in European Journal of Computational Mechanics (2008), 17/5-7

We present an application of X-FEM to the fracture analysis of piezoelectric materials. These materials are increasingly used in actuators and sensors. Under in service loading, phenomena of crack ... [more ▼]

We present an application of X-FEM to the fracture analysis of piezoelectric materials. These materials are increasingly used in actuators and sensors. Under in service loading, phenomena of crack initiation and propagation may occur due to high electromechanical field concentrations. In the past few years, the extended finite element method (X-FEM) has been applied mostly to model cracks in structural materials. The present paper focuses on the definition of new enrichment functions suitable for cracks in piezolectric structures. The approach is based on specific asymptotic crack tip solutions, derived for piezoelectric materials. [less ▲]

Detailed reference viewed: 86 (6 ULg)
Peer Reviewed
See detailFracture prevention
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Clinical Evidence (2001), 5

Detailed reference viewed: 7 (3 ULg)
Full Text
Peer Reviewed
See detailFracture prevention in osteoporosis: assessing risks, providing solutions.
Reginster, Jean-Yves ULg; Brandi, M. L.

in Osteoporosis International (2010), 21 Suppl 2

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailFracture prevention in postmenopausal women
Bruyère, Olivier ULg; Edwards, John; Reginster, Jean-Yves ULg

in Clinical Evidence (2005), 13

Detailed reference viewed: 20 (13 ULg)
Peer Reviewed
See detailFracture prevention in postmenopausal women
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Clinical Evidence (2001), 6

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailFracture prevention in postmenopausal women.
Bruyère, Olivier ULg; Edwards, John; Reginster, Jean-Yves ULg

in Clinical Evidence (2002), 8

Detailed reference viewed: 33 (23 ULg)
Full Text
Peer Reviewed
See detailFracture prevention in postmenopausal women.
Bruyère, Olivier ULg; Edwards, John; Reginster, Jean-Yves ULg

in Clinical Evidence (2003), 9

Detailed reference viewed: 18 (9 ULg)
Full Text
Peer Reviewed
See detailFracture prevention. New topic
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Clinical Evidence (2000), 4

Detailed reference viewed: 27 (5 ULg)
Full Text
Peer Reviewed
See detailFracture risk and zoledronic acid therapy in men with osteoporosis
Boonen, S.; REGINSTER, Jean-Yves ULg; Kaufman, J.-M. et al

in New England Journal of Medicine (2012), 367(18), 1714-1723

BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk ... [more ▼]

BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 months. Participants received daily calcium and vitamin D supplementation. The primary end point was the proportion of participants with one or more new morphometric vertebral fractures over a period of 24 months. RESULTS: The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over the 24-month period, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence interval, 0.16 to 0.70; P = 0.002). As compared with men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral fractures (P = 0.03) and less height loss (P = 0.002). Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral fractures, although this difference did not reach significance because of the small number of fractures. Bone mineral density was higher and bone-turnover markers were lower in the men who received zoledronic acid (P<0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%). CONCLUSIONS: Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.) Copyright © 2012 Massachusetts Medical Society. [less ▲]

Detailed reference viewed: 27 (7 ULg)
Full Text
Peer Reviewed
See detailFracture risk in women ≥ 65 years with once-monthly oral bisphosphonate compared with weekly bisphosphonates: subanalysis from the evaluation of ibandronate efficacy (VIBE) database study.
Siverman, S.; Poston, S.; Blumenthals, W. et al

in Osteoporosis International (2009, March), 20(Suppl.1), 153

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailFracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
Delmas, P. D.; Licata, A. A.; Reginster, Jean-Yves ULg et al

in BONE (2006), 39(2), 237-243

Introduction: Teriparatide is a bone formation agent that increases bone turnover and mass, resulting in an increase in bone strength and a decrease in fracture risk. Methods: The primary purpose of this ... [more ▼]

Introduction: Teriparatide is a bone formation agent that increases bone turnover and mass, resulting in an increase in bone strength and a decrease in fracture risk. Methods: The primary purpose of this analysis was to evaluate the association between pretreatment bone turnover marker (BTM) concentrations and the absolute and relative fracture risks after adjusting for baseline femoral neck BMD, number of prevalent vertebral fractures, and age. Because femoral neck BMD is commonly attained in the assessment of patients at risk for osteoporosis, we examined the ability of a multivariate assessment including pretreatment BTM concentration and femoral neck BMD to predict future fracture risk after adjusting for the number of prevalent vertebral fractures. We examined data from the Fracture Prevention Trial, a study designed to determine the effect of teriparatide 20 mcg/day and teriparatide 40 mcg/day on vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis. BTM were analyzed in two subsets of women within the Fracture Prevention Trial, and included serum bone-specific alkaline phosphatase (BSAP), serum carboxyterminal extension peptide of procollagen type I (PICP), serum amino-terminal extension peptide of procollagen type I (PINP), urinary free deoxypyridinoline (DPD), and urinary N-terminal telopeptide (NTX). Results: Teriparatide significantly reduced the risk of fracture [four BTM subset (n = 520), placebo = 14.3%, teriparatide = 5.8%, P < 0.05; PINP subset (n = 771), placebo = 17.7%, teriparatide = 5.5%, P < 0.05]. Subjects with the highest pretreatment BTM concentrations had the greatest fracture risk. Teriparatide-mediated absolute risk reduction was greatest for women with high pretreatment bone turnover; however, the relative fracture risk reduction was independent of pretreatment bone turnover. After adjusting for pretreatment BTM and number of prevalent vertebral fractures, baseline femoral neck BMD was not a significant predictor of fracture risk. Conclusion: Teriparatide-mediated relative fracture risk reduction was independent of pretreatment bone turnover, demonstrating that this therapy offers clinical benefit to patients across a range of disease severity. (c) 2006 Elsevier Inc. All rights reserved. [less ▲]

Detailed reference viewed: 24 (2 ULg)